Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — Technical Presentation (July 2024)

13 slides from Eyepoint's technical presentation, July 2024

  1. Slide 1: Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial

    Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration Veeral S. Sheth1 on behalf of DAVIO 2 investigators and coauthors David A. Eichenbaum,2 Vrinda Hershberger,3 Sunil Patel,4 Ashkan M. Abbey,5 William Z. B

  2. Slide 2: Presenter Disclosures

    Presenter Disclosures Speaker: Genentech and IvericBio Consultant: Apellis, EyePoint, Genentech, IvericBio, Kriya Therapeutics, Novartis, Ocular Therapeutix, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity, Vial Contracted research: 4D Molecular Therapeutics, Abbvie, Adverum Biotechn

  3. Slide 3: EYP-1901 (DURAVYU): Vorolanib in Durasert E

    EYP-1901 (DURAVYUTM [vorolanib intravitreal insert]): Vorolanib in Durasert ETM EYP-1901 Vorolanib Durasert E Controlled release over a Potent receptor tyrosine kinase Bioerodible, sustained period of at least 6 months inhibitor (TKI): selectively inhibits all IVT drug delivery VEGF signaling No del

  4. Slide 4: DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD

    DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD Baseline Primary endpoint characteristics EYP-1901 dosing Blend W28 & W32 ~2 years since diagnosis 161 patients W36 to mean; range, 0.1–20 years D1 W4 W8 W12 W16 W20 W24 W28 W32 W56 EYP-1901 2 mg low dose ~10 anti-VEGF i

  5. Slide 5: DAVIO 2: EYP-1901 maintained vision and CST; well tolerated

    DAVIO 2 EYP-1901 maintained vision and CST Week 32 EYP-1901 well-tolerated with an acceptable safety profile Primary endpoint Mean BCVA change 10 Key Safety Findings BCVA change from baseline, mean ± SD ETDRS letters 5 • No reported ocular 0 SAEs, systemic SAEs, or discontinuations -5 related to EYP

  6. Slide 6: Objective: Understand patterns of supplemental injections in DAVIO 2

    OBJECTIVE: Understand patterns of supplemental injections in DAVIO 2 BCVA reduction ≥5 letters from best on-study measurement due to wet AMD AND CST increase ≥75 µm from lowest on-study measurement OR BCVA reduction ≥10 letters from best on-study • How many patients Prespecified measurement due to w

  7. Slide 7: Two-thirds of eyes receiving EYP-1901 were supplemental injection-free up to Week 32

    Two-thirds of eyes receiving EYP-1901 were supplemental injection–free up to Week 32 EYP-1901 dosing 100% 100% 98% 96% 96% 94% 100% Eyes supplemental injection–free 100% 98% 79% up to specified week, % 80% 74% 87% 63% 100% 98% 60% 75% 70% 84% 63% 40% 20% 0% Week 8 Week 12 Week 16 Week 20 Week 24 Wee

  8. Slide 8: Two-thirds of eyes receiving EYP-1901 were supplemental injection-free up to Week 32

    Two-thirds of eyes receiving EYP-1901 were supplemental injection–free up to Week 32 % of patients with supplemental injections EYP-1901 dosing up to Week 32 % of patients supplement-free 100% 100% Number of injections 98% 961% 96% 94% 100% Aflibercept q8W 2+ Eyes supplemental injection–free 100% 98

  9. Slide 9: Reasons for supplemental injections were distributed across criteria

    Reasons for supplemental injections were distributed across criteria Received supplemental injections per prespecified criteriaa 24% (12/50) 31% (16/52) of EYP-1901 2 mg patients of EYP-1901 3 mg patients Criteria met Per injection; supplemental injections meeting multiple criteria are counted onceb

  10. Slide 10: Some EYP-1901-treated patients received supplemental injections without meeting prespecified criteria

    Some EYP-1901–treated patients received supplemental injections without meeting prespecified criteria Received supplemental injections while never meeting prespecified criteria 12% (6/50) 6% (3/52) of EYP-1901 2 mg patients of EYP-1901 3 mg patients Supplemental injections Reasons provided by invest

  11. Slide 11: Nearly identical BCVA change with EYP-1901 and aflibercept at 12 months

    Month 12 DAVIO 2 results Nearly identical BCVA change with EYP-1901 and aflibercept at 12 months Mean change vs aflibercept 2 mg q8W EYP-1901 dosing Aflibercept 2 mg q8W −0.5 10 (n = 50) EYP-1901 2 mg +0.4 −0.1 (n = 47) letters BCVA change from baseline, EYP-1901 3 mg +0.0 5 −0.5 (n = 52) letters me

  12. Slide 12: Summary

    Summary • DAVIO 2 was the largest IVT TKI trial to date • EYP-1901 maintained stable visual acuity with strong anatomical control over 32 weeks • EYP-1901 was well-tolerated, with no related ocular or systemic SAEs • Two-thirds of EYP-1901-treated eyes were supplement-free up to 32 weeks • Reasons f

  13. Slide 13: EYP-1901 in wet AMD: Phase 3 pivotal trial design

    LUGANO EYP-1901 in wet AMD: Phase 3 pivotal trial design LUCIA LUGANO & LUCIA: Patients with wet AMD, previously-treated or treatment-naïve Primary endpoint Blend W52 & W56 EYP-1901 dosing EYP-1901 dosing EYP-1901 dosing W60 to W84 to W96 D1 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W80

EyePoint Pharmaceuticals — Technical Presentation (July 2024) on 6ix